Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss ... Aligos Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.63 million ...

Alagille Syndrome (ALGS) is a genetic, multisystem disorder that affects several organs in the body such as the liver, heart, and skeletal system. It is a complex condition with different symptoms and ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Genetic engineering is the act of modifying the genetic makeup of an organism. Modifications can be generated by methods such as gene targeting, nuclear transplantation, transfection of synthetic ...

Chromosomal-level aphid genome comparisons provide new insights into chromosomal evolutionary patterns and detoxification gene families evolution in aphids, aiding the understanding of species ...

Mar. 10, 2025 — Researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in ...